BioSpace News Archive

Drug Development

Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022

Exelixis, Inc. announced results from the dose-escalation stage of STELLAR-001, an ongoing phase 1b trial evaluating XL092 as a single-agent and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors.

September 10, 2022
·
18 min read
Drug Development

Wugen Presents Preclinical Data on WU-NK-101 in Solid Tumor Models at the European Society for Medical Oncology (ESMO) Congress 2022

Wugen, Inc. presented preclinical data on WU-NK-101, the company’s lead memory natural killer cell therapy product, in a poster session at the European Society for Medical Oncology Congress 2022, taking place in Paris, France from September 9-13, 2022.

September 10, 2022
·
3 min read
Drug Development

Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

Immatics N.V. announced a comprehensive preclinical data set for its T cell engaging receptor product candidate IMA402 at the European Society for Medical Oncology Congress 2022 held in Paris, France, from September 9 to 13, 2022.

September 10, 2022
·
8 min read
Drug Development

New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100

AbbVie announced new, long-term data analyses of KEEPsAKE 1 and 2, Phase 3 trials evaluating SKYRIZI® in adult patients with active psoriatic arthritis.

September 10, 2022
·
12 min read
BioMidwest

Exact Sciences Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation at the 2022 European Society for Medical Oncology Congress

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced data from a multi-cancer early detection biomarker validation study was presented at the European Society for Medical Oncology Congress.

September 10, 2022
·
6 min read
Pharm Country

Eisai Presents Results of Post-Hoc Analysis of Eribulin Mesylate (HALAVEN®) at the European Society for Medical Oncology (ESMO) Congress 2022

Eisai announced results from a post-hoc analysis of three randomized, pivotal, Phase 3 studies evaluating the efficacy of eribulin mesylate versus other chemotherapies in patients living with metastatic breast cancer whose tumors have low or no HER2 expression.

September 10, 2022
·
9 min read
Biotech Bay

Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer

Exai Bio, a next-generation liquid biopsy company, and researchers at UCSF are presenting data from a new study in a poster entitled “Serum-based colorectal cancer detection using orphan noncoding RNAs” at the 2022 European Society of Medical Oncology meeting.

September 10, 2022
·
3 min read
Drug Development

Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022

Apexigen, Inc. announced the presentation of new data from a Phase 2 multicenter clinical trial evaluating sotigalimab, Apexigen’s agonist antibody targeting CD40, in combination with neoadjuvant chemoradiation for patients with resectable esophageal and gastroesophageal junction cancers.

September 10, 2022
·
8 min read
BioMidwest

CORRECTING and REPLACING James Johnston named to Greyledge Technologies Board of Directors

James Johnston, an innovative executive with extensive financial and strategic experience with global organizations, has joined the board of directors of Greyledge Technologies, Inc.

September 10, 2022
·
4 min read
Drug Development

CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination

CatalYm, presented data from its first-in-human GDFather-1 trial at the European Society for Medical Oncology Congress 2022 held in Paris, France.

September 10, 2022
·
7 min read